Discontinued — last reported Q3 '24
Forteo® — Revenue
Eli Lilly Forteo® — Revenue increased by 69.0% to $118.10M in Q3 2024 compared to the prior quarter. Year-over-year, this metric declined by 19.3%, from $146.40M to $118.10M. Over 2 years (FY 2021 to FY 2023), Forteo® — Revenue shows a downward trend with a -18.5% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates strong market penetration or sustained demand for the therapy, while a decrease often signals the impact of patent expirations, generic entry, or shifts in clinical prescribing patterns.
Detailed definition
This metric represents the total global net sales generated from the Forteo product line, which is a therapeutic treatme...
Peer comparison
Comparable to revenue reporting for mature, off-patent, or specialty pharmaceutical products at peer companies like Amgen or Merck, where lifecycle management is critical to cash flow.
lly_segment_forteo_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $218.40M | $200.90M | $184.10M | $137.40M | $138.50M | $177.10M | $160.10M | $122.30M | $148.00M | $146.40M | $116.50M | $61.30M | $69.90M | $118.10M |
| QoQ Change | — | -8.0% | -8.4% | -25.4% | +0.8% | +27.9% | -9.6% | -23.6% | +21.0% | -1.1% | -20.4% | -47.4% | +14.0% | +69.0% |
| YoY Change | — | — | — | — | -36.6% | -11.8% | -13.0% | -11.0% | +6.9% | -17.3% | -27.2% | -49.9% | -52.8% | -19.3% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's forteo® — revenue?
- Eli Lilly (LLY) reported forteo® — revenue of $118.10M in Q3 2024.
- How has Eli Lilly's forteo® — revenue changed year-over-year?
- Eli Lilly's forteo® — revenue decreased by 19.3% year-over-year, from $146.40M to $118.10M.
- What is the long-term trend for Eli Lilly's forteo® — revenue?
- Over 2 years (2021 to 2023), Eli Lilly's forteo® — revenue has grown at a -18.5% compound annual growth rate (CAGR), from $801.90M to $533.20M.
- What does forteo® — revenue mean?
- The total revenue generated from sales of the osteoporosis medication Forteo.